Search Cancer Clinical Trials

Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
7 results
  • Liver Cancer, Sarcoma, Thyroid Cancer, Pancreatic Cancer, Head and Neck Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Kidney Cancer

23-301          Phase I

A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants with Advanced Solid Tumors

  • Ovarian Cancer, Gastric (Stomach) Cancer, Sarcoma

24-169          Phase I

A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor M1774

  • Bladder Cancer, Endometrial Cancer, Esophageal Cancer, Gastric (Stomach) Cancer, Liver Cancer, Pancreatic Cancer, Sarcoma

20-544          Phase II

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation

  • Bladder Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Lung Cancer, Kidney Cancer, Gastric (Stomach) Cancer, Pancreatic Cancer, Sarcoma, Prostate Cancer

23-392          Phase I

A Phase 1a/1b, Dose-Escalation/Dose-Expansion study of NPX267 in Subjects with Solid Tumors Known to Express HHLA-2

  • Sarcoma

21-492          Phase II

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma

  • Prostate Cancer, Pancreatic Cancer, Sarcoma, Breast Cancer, Gastric (Stomach) Cancer, Colorectal Cancer, Ovarian Cancer

21-304          Phase I

Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid Tumors

  • Sarcoma

23-606          Phase II

Randomized, Controlled, Open-label, Phase IIb/III Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Patients with Metastatic Leiomyosarcoma

Showing 1 - 10 of 7 results